Table 2.
Patient preference | Age | Risk group | PO a | WP | WP | Optimal choice d |
---|---|---|---|---|---|---|
Min-complications | 60 | intermediate | 12.0 | 11.4 | 11.0 | PO |
60 | high | 9.4 | 9.9 | 8.8 | MD | |
75 | intermediate | 7.1 | 6.7 | 6.4 | PO | |
75 | high | 5.8 | 5.9 | 5.3 | MD | |
Population average | 60 | intermediate | 12.3 | 12.6 | 12.1 | MD |
60 | high | 9.8 | 11.1 | 10.0 | WP | |
75 | intermediate | 7.2 | 7.3 | 7.1 | MD | |
75 | high | 6.0 | 6.6 | 6.1 | WP | |
Max life | 60 | intermediate | 12.5 | 13.1 | 12.7 | WP |
60 | high | 9.9 | 11.7 | 10.5 | WP | |
75 | intermediate | 7.3 | 7.7 | 7.4 | WP | |
75 | high | 6.1 | 7.0 | 6.3 | WP |
aPO = prostate-only RT
b WP65 %= whole pelvic RT assuming a 65% cure rate for occult lymph node disease
c WP20 %= whole pelvic RT assuming a 20% cure rate for occult lymph node disease
dMD = optimal choice depends upon physician belief in efficacy of nodal irradiation
Patients are stratified by age, disease risk group and attitude towards the balance between quantity and quality of life